Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

Fig. 3

Association of PD-L1 expression with survival in the entire cohort. a Kaplan-Meier curves of overall survival between tumors with positive and negative PD-L1 expression by IC in the subgroup with neoadjuvant chemotherapy (NACT). b Kaplan-Meier curves of overall survival between tumors with positive and negative PD-L1 expression by TCIC in the subgroup with NACT

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us